• Home
  • Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma.

Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma.

Author List
Kelley RK
Publication
Gastroenterology & hepatology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/486528084
Publication Year
2024
PubMed ID
38414909
Publication Title
Kelley RK. Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2024 Feb; 20(2):119-122.